Koers BIOLASE Inc Nasdaq
Aandelen
US0909111082
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 50,67 mln. 46,68 mln. | Omzet 2025 * | 54,66 mln. 50,35 mln. | Marktkapitalisatie | 5,33 mln. 4,91 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -10 mln. -9,21 mln. | Nettowinst (verlies) 2025 * | -6 mln. -5,53 mln. | EV/omzet 2024 * | 0,11 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,1 x |
K/w-verhouding 2024 * |
-0,36
x | K/w-verhouding 2025 * |
-1,68
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,67% |
Recentste transcriptie over BIOLASE Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Beaver
CEO | Chief Executive Officer | 62 | 01-10-17 |
Director of Finance/CFO | 53 | 01-02-21 | |
Steven Sandor
COO | Chief Operating Officer | 44 | 01-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Lord
CHM | Chairman | 69 | 01-08-14 |
John Beaver
CEO | Chief Executive Officer | 62 | 01-10-17 |
Director/Board Member | 73 | 16-08-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,18% | 227 mld. | |
+15,22% | 198 mld. | |
+19,19% | 142 mld. | |
+30,89% | 111 mld. | |
+1,56% | 64,16 mld. | |
+18,48% | 54,1 mld. | |
+5,12% | 51,41 mld. | |
+10,53% | 45,32 mld. | |
+5,98% | 37,32 mld. |